ArticleJTO clinical and research reports2025

Monotherapy With Immune Checkpoint Blockade Improves Survival Outcomes in KRAS-Mutant but Not KRAS Wild-Type Metastatic Lung Adenocarcinoma: Validation From an Extended Swedish Cohort.

Ella A Eklund et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.